Home Other Building Blocks 1195765-45-7
1195765-45-7,MFCD17215684
Catalog No.:AA000IVZ

1195765-45-7 | Dabrafenib

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$6.00   $4.00
- +
250mg
98%
in stock  
$65.00   $46.00
- +
1g
98%
in stock  
$162.00   $114.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA000IVZ
Chemical Name:
Dabrafenib
CAS Number:
1195765-45-7
Molecular Formula:
C23H20F3N5O2S2
Molecular Weight:
519.5624
MDL Number:
MFCD17215684
SMILES:
Nc1nccc(n1)c1sc(nc1c1cccc(c1F)NS(=O)(=O)c1c(F)cccc1F)C(C)(C)C
Properties
Computed Properties
 
Complexity:
817  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
35  
Hydrogen Bond Acceptor Count:
11  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
6  
XLogP3:
4.8  

Literature

Title: Antiseptic effects of dabrafenib on TGFBIp-induced septic responses.

Journal: Chemico-biological interactions 20171225

Title: Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption.

Journal: Chemico-biological interactions 20160825

Title: Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

Journal: British journal of cancer 20160315

Title: Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.

Journal: Scientific reports 20160101

Title: Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Journal: Expert opinion on drug metabolism & toxicology 20130701

Title: BRAF inhibitor activity in V600R metastatic melanoma.

Journal: European journal of cancer (Oxford, England : 1990) 20130301

Title: BRAF inhibition and beyond in advanced melanoma.

Journal: Lancet (London, England) 20120728

Title: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Journal: Lancet (London, England) 20120728

Title: Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.

Journal: Archives of dermatology 20120301

Title: Small molecule inhibitors of BRAF in clinical trials.

Journal: Bioorganic & medicinal chemistry letters 20120115

Title: Overcoming metastatic melanoma with BRAF inhibitors.

Journal: Archives of pharmacal research 20110501

Title: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Journal: Nature 20100930

Title: Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther, 2012, 11(4), 909-920.

Title: Lee S, et al. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption. Chem Biol Interact. 2016 Jul 22.

Title: Jung B, et al. Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses. BMB Rep. 2016 Apr;49(4):214-9.

Title: Alexander M Menzies, et al. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012; 6: 391–405.

Title: Posobiec LM, et al. Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation. Birth Defects Res B Dev Reprod Toxicol. 2015 Dec;104(6):244-52.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:1195765-45-7 Molecular Formula|1195765-45-7 MDL|1195765-45-7 SMILES|1195765-45-7 Dabrafenib